Physician profile
Ruby Wu
NPI 1568758753
$850.58
in general payments reported to CMS, 2019-2025
10 companies · $443 in 2025
The $443 reported for 2025 was more than what 84% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2023: $241 · 2024: $44.18 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $203.39 | 2025 | |
| Daiichi Sankyo INC. | $175.72 | 2023-2025 | Enhertu |
| Deciphera Pharmaceuticals INC. | $121.68 | 2021 | |
| Telix Pharmaceuticals | $118.93 | 2023 | |
| Stemline Therapeutics INC. | $92.74 | 2025 | Orserdu |
| Astrazeneca Pharmaceuticals Lp | $54.49 | 2025 | Calquence |
| Genentech USA, INC. | $22.62 | 2024 | Itovebi |
| Chiesi USA, INC. | $21.56 | 2024 | Ferriprox |
| Syndax Pharmaceuticals, INC. | $20.59 | 2025 | Revuforj |
| Puma Biotechnology, INC. | $18.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.